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Abstract
Most of the drugs in use against Plasmodium falciparum share similar modes of action and, consequently, there is a need to
identify alternative potential drug targets. Here, we focus on the apicoplast, a malarial plastid-like organelle of algal source
which evolved through secondary endosymbiosis. We undertake a systematic in silico target-based identification approach
for detecting drugs already approved for clinical use in humans that may be able to interfere with the P. falciparum
apicoplast. The P. falciparum genome database GeneDB was used to compile a list of <600 proteins containing apicoplast
signal peptides. Each of these proteins was treated as a potential drug target and its predicted sequence was used to
interrogate three different freely available databases (Therapeutic Target Database, DrugBank and STITCH3.1) that provide
synoptic data on drugs and their primary or putative drug targets. We were able to identify several drugs that are expected
to interact with forty-seven (47) peptides predicted to be involved in the biology of the P. falciparum apicoplast. Fifteen (15)
of these putative targets are predicted to have affinity to drugs that are already approved for clinical use but have never
been evaluated against malaria parasites. We suggest that some of these drugs should be experimentally tested and/or
serve as leads for engineering new antimalarials.
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Introduction
Malaria remains a serious public health problem in many
tropical countries [1]. As there is still no effective vaccine available,
treatment and prevention of the disease is primarily based on
antimalarial drug administration and anti-vector measures,
respectively. The efficacy of antimalarial drug treatment is
compromised by the malaria parasite’s ability to develop drug-
resistance, and by the dearth of new and effective antimalarials in
the drug-design pipeline. There is, therefore, an urgent need for
the discovery of new antimalarial drugs.
The main antimalarials presently approved for clinical use act
mainly on two parasite metabolic pathways: haemoglobin
degradation and nucleic acid synthesis. However, with the
exception of artemisinin derivatives, parasite resistance has
evolved and become common for the currently used antimalarial
drugs. One of the underlying phenomena contributing to the
emergence of drug resistance, is that resistance to different drugs is
often controlled by similar molecular mechanisms and conse-
quently the evolution of resistance to one particular compound
may impact on the efficacy of others. For instance, resistance to
quinine-derived drugs, such as mefloquine and lumefantrine, as
well as to the structurally unrelated artemisinin derivatives, has
been shown to be modulated by mutations and/or amplification of
the Multidrug Resistance Protein homologue-1, PfMDR1 [2].
Similarly, resistance to drugs that block parasite nucleic acid
synthesis, such as sulfadoxine, pyrimethamine and proguanil, is
largely conferred by point mutations in genes encoding two
enzymes, dihydrofolate reductase (DHFR) and the dihydroptero-
ate synthase (DHPS) [3].
When considering the design of new antimalarial drugs, it is,
therefore, imperative to investigate alternative antimalarial mo-
lecular targets. One such strategy has focused on the apicoplast, a
non-photosynthetic malarial plastid which was first described in
the 1990’s [4,5] and recently confirmed to have been acquired by
secondary endosymbiosis of a plastid-containing red alga [6]. The
apicoplast’s genome is small (<35 kb), and the organelle harbors
several unique metabolic functions, mostly accomplished by
proteins that are nuclear-encoded and later imported into its
lumen [7]. These unique metabolic features represent an attractive
starting point for therapeutic intervention, since they are mostly of
plant/algal origin, a fact that may heighten the target selectivity of
antimalarial drugs and/or reduce the probabilities of toxicity to
humans. Importantly, previous studies have already confirmed
that the apicoplast is vulnerable to drugs that affect its metabolic
functions, such as replication, nucleic acid metabolism, translation,
fatty acid synthesis and isoprenoid biosynthesis [8].
A conventional drug development strategy may involve both de
novo drug discovery and the improvement of inhibitors of
individually validated targets. Although this process represents
an efficient strategy to develop novel antimalarial drugs, it is
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usually costly and time-consuming. An alternative and/or
complementary approach is to screen existing clinically approved
drugs for previously unidentified antimalarial activity, thus
speeding up the discovery of new therapies. As such drugs are
already approved for use in humans for other purposes, they can
more easily enter human clinical efficacy trials under existing drug
administration guidelines.
There are a number of different publicly available web-based
databases which provide information on thousands of known
therapeutic protein targets, the diseases that they are involved in,
evidence for which pathways they play a role in, and the
corresponding drugs which are directed at each of them. Using
three of these databases, DrugBank [9], STITCH3.1 [10] and
Therapeutic Target Database (TTD) [11], we adopted an in silico
‘‘top-down’’ approach to identify proteins localized to the P.
falciparum apicoplast that may be targeted by drugs which are
already in use in human clinical practice.
Materials and Methods
Compilation of a List of Apicoplast-targeted Proteins
A list of Plasmodium falciparum apicoplast-targeted proteins has
been previously published by Ralph et al, 2004 [7]. The
description of the methods that were used to identify proteins
predicted to contain apicoplast-targeting sequences is detailed in
that paper [7]. For the present work, this list was accessed and
each protein entry was logged on to an Excel file datasheet.
Proteins were grouped consecutively in a datasheet column
depending on their predicted metabolic function and according
to the classification available in the ‘‘Malaria Parasite Metabolic
Pathways’’ web page [12]. Their identification codes (IDs) were
then retrieved from the GeneDB P. falciparum genome database
[13] and logged onto the corresponding column as a clickable
hyperlink. We further checked the annotation of each single
predicted peptide and corrected it, if necessary, according to the
recent updated annotations of the GeneDB database. Next, we
retrieved each individual predicted amino acid sequence and
copied it to the corresponding column for each protein.
Identification of Putative Drug Targets Using Publicly
Available Drug Databases Overall Strategy
Each of the P. falciparum predicted protein sequences from the
list compiled above was treated as a putative drug-target and
consequently used to interrogate three different publicly
available web databases that provide synoptic data on drugs
and their primary or putative drug targets: DrugBank [9],
STITCH3.1 [10] and the Therapeutic Target Database (TTD)
[11]. Our search strategy for all three databases was based on
the principle of ‘‘target similarity’’ whereby each query (P.
falciparum apicoplast protein) is compared for similarity with all
known drug targets contained within each of the databases. In
cases where homologous drug targets were identified, all
proteins with an output expectation value (E-value) lower than
1e25 for DrugBank and TTD were listed as potential targets.
In the case of STICH3.1, a score from 0 to 1.0 is given, rather
than an expectation value. Thus, only proteins with a score
above 0.7 were considered potential targets. We further filtered
all positively identified targets through inclusion in the list of
only those proteins that were indicated to interact with
compounds that have already been approved for clinical use
in humans.
Database Commands for DrugBank [9]
Starting from the homepage, the option ‘‘search’’ R ‘‘sequence
search’’ was chosen from the toolbar menu. The query protein
sequence was then entered in FASTA format and the remaining
default search parameters were used.
Database Commands for STITCH3.1 [10]
Starting from the homepage, the option ‘‘protein sequence’’
from the menu box was clicked. The query protein sequence was
then entered in FASTA format and the ‘‘Go’’ icon was clicked.
When positive results were obtained only targets with a score
above 0.7 were considered.
Database Commands for Therapeutic Targets Database
[11]
Starting from the homepage, the option ‘‘target similarity
search’’ from the menu box was clicked. The query protein
sequence was then entered in FASTA format and the ‘‘Search’’
icon was clicked. When positive results were obtained only targets
with an Expectation value (E-value) score lower than 1e25 were
considered for further analyses.
Compilation of the ‘‘Predicted Targets List’’
After running each of the P. falciparum protein sequences in the
three databases, all proteins with negative results (negative hits)
were excluded from further analyses, whilst predicted targets from
each database were compiled into a single Excel file, hereafter
named ‘‘predicted targets list’’. The following parameters associ-
ated with each positive hit were entered into the spreadsheet:
‘‘Homologous target(s) name(s) and target ID(s)’’ (DrugBank and
TTD), ‘‘E-value(s) or score(s)’’ (DrugBank, STITCH3.1 and
TTD), ‘‘Drug type(s)’’ (DrugBank, STITCH3.1 and TTD), ‘‘Drug
name(s)’’ (DrugBank, STITCH3.1 and TTD), ‘‘Drug ID(s)’’
(DrugBank) and ‘‘Toxicity’’ (DrugBank).
Each positive hit was further cross-examined in the TDR targets
Database [14] for its ‘‘druggability index’’, which is an estimate of
the likelihood of a protein being druggable and ranges from 0 to
1.0, with a value of <0.2 corresponding to average druggability.
To do this, we clicked on the ‘‘targets’’ item in the web site’s menu
and then ticked ‘‘Plasmodium falciparum’’ from the pathogen species
list. We next filtered targets by entering each protein’s identifier
(ID) in the corresponding box in the ‘‘Filter targets based on’’
search options. After clicking on the ‘‘search’’ icon, the above
variable was retrieved from the target’s page and was subsequently
recorded in the ‘‘predicted targets list’’ file.
List of Drugs Yet to be Tested Against Malaria
Finally, we carried out a literature search using PubMED in
order to identify approved drugs that have never been evaluated
against malaria parasites by querying all drugs associated with
each positive hit in the list. Our definition of ‘‘evaluation’’
embraces in vitro and/or in vivo testing and any malaria parasite
species. Therefore if a given drug is noted as ‘‘not tested’’, it means
that no publication records were found after either of the following
search details were entered in PubMED: 1. (‘‘drug name’’[MeSH
Terms] OR ‘‘drug name’’[All Fields]) AND (‘‘plasmodium’’[-
MeSH Terms] OR ‘‘plasmodium’’[All Fields]) and 2. (‘‘drug
name’’[MeSH Terms] OR ‘‘drug name’’[All Fields]) AND
(‘‘malaria’’[MeSH Terms] OR ‘‘malaria’’[All Fields]), or that the
study(ies) retrieved were insufficiently informative to infer the
potential usefulness of the drug as an antimalarial.
Antimalarial Drugs
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Results
Schematic Summary
For ease of understanding, the overall results of this work are
represented as a flow chart in Figure 1, the detailed results of
which are given in the following sections.
Compilation of the ‘‘Predicted Targets’’ List
Each of the Plasmodium falciparum proteins predicted to contain
an apicoplast target signal was entered into a single Excel file as
described in Materials and Methods. A list of a total 595 candidate
target protein sequences was thus compiled and each was
subsequently allocated either of the following predicted metabolic
functions: ‘‘Replication, Transcription and Nucleic acid metabo-
lism’’, ‘‘Translation’’, ‘‘Fatty acid and Phospholipid Metabolism’’,
‘‘Transport’’, ‘‘Antioxidant’’, ‘‘Protein Folding’’, ‘‘Fe-S Cluster
Production’’, ‘‘Porphyrin Biosynthesis’’, ‘‘Post-translational Mod-
ification and Proteolysis’’ and ‘‘Other/unknown function’’ (Table
S1). Each of these protein sequences in the list was interrogated for
target similarity in the three databases used (DrugBank,
STITCH3.1 and TTD), producing a list of a total seventy-two
(72) ‘‘positive hits’’ (<12% of the total predicted apicoplast
peptides) (Table S2). We decided to use all three databanks
because each of them may contain different drug-target datasets
and, consequently, the probability of targets being missed due to
insufficient screening is reduced. Indeed, no single database was
capable of identifying all 72 predicted targets: DrugBank,
STICH3.1 and TTD identified exclusively 45, 8 and 11 predicted
targets, whilst the remaining 8 targets were identified by two or
three of the databases. Detailed information about the predicted
targets and their associated compounds is provided in Table S2.
Approximately one third of the positively identified targets
(N = 25) were predicted to react with compounds belonging to the
‘‘Dietary supplement/nutraceutical’’ class. Since these compounds
are unlikely to exhibit antimalarial activity, these targets and their
associated compounds were excluded from further analyses. The
distribution of the remainder 47 potential targets according to
their predicted metabolic function is depicted in Figure 2. Eighty
percent (80%, N = 38) of these 47 positive hits are distributed
between four main metabolic function groups: ‘‘Replication,
Transcription and Nucleic acid metabolism’’, ‘‘Translation’’,
‘‘Fatty acid and Phospholipid Metabolism’’ and ‘‘Post-translation-
al Modification and Proteolysis’’.
Previously Untested Drugs
In order to evaluate which of the drugs associated with the
predicted targets had been tested against malaria parasites and
which had not, we ran a literature search in PubMed as described
above. Out of a total of 47 positive hits from the list compiled
above, 32 targets were associated with drugs whose activity has
been previously evaluated against malaria parasites. Examples of
some of these drugs and their corresponding targets are given in
Table 1. However, for 15 of the predicted targets, there were a
total of 13 corresponding drugs that have never been experimen-
tally or clinically tested against malaria or whose evaluation
required further studies (Table 2). The metabolic functions
predicted to be targeted by each of these drugs in the apicoplast
are the following: Replication, Transcription and Nucleic acid
metabolism (5 drugs: azelaic acid, lucanthone, bleomycin,
rifabutin and gemcitabine), Fatty acid and Phospholipid Metab-
olism (3 drugs: ethionamide, nitrofurazone and isoxyl) and post-
translational modification and proteolysis (5 drugs: nitroxoline,
gallium nitrate, sulcrafate, remikeren and aliskeren). Two of these
drugs (azelaic acid and sulcrafate) are predicted to interfere with
more than one peptide and one particular predicted target
(plasmepsin X) is expected to have affinity to more than one drug.
The list of these drugs, their targets, associated toxicity (if any) and
each target’s druggability index is depicted in Table 2.
Discussion
The main objective of this work was to identify drugs that have
been approved for clinical use in humans for conditions other than
malaria, which may have the potential to interfere with the
function of the apicoplast. In validation of our approach, all the
main drugs previously shown to target the apicoplast and their
known targets were identified by our methodology (Table S2,
Table 1) and the following illustrative examples are given. The
Figure 1. Flowchart summarizing the work pipeline and corresponding results. (*denotes the targets that were discarded on the basis of
having chemical affinity to dietary supplements/nutraceuticals).
doi:10.1371/journal.pone.0059288.g001
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antibiotics ciprofloxacin and doxycycline and their respective
targets, the apicoplast’s DNA gyrase and small ribosomal subunits
[8], were correctly pinpointed by our approach. Fosmidomycin, a
drug that is known to target the apicoplast’s 1-deoxy-D-xylulose 5-
phosphate reductoisomerase (DOXP) [15,16], was appropriately
identified. Fusidic acid and its likely target, elongation factor G
[17], involved in the process of translation, were correctly
pinpointed and associated. Consequently, we were confident that
our overall strategy for identifying anti-apicoplast drugs is valid.
Following this precondition, we were able to identify thirteen
drugs that have not yet been evaluated against malaria parasites.
These drugs are supposed to inhibit targets that are involved in
metabolic functions of the apicoplast that have been shown to
render the parasite vulnerable to drugs [8]. For this reason we
suggest that the antimalarial activity of at least some of these
compounds should be investigated further. In the ensuing
paragraphs we refer specifically to five of these drugs that we
suggest may be good candidates for antimalarial testing,
highlighting their advantages but also the constraints that may
limit their direct use in vivo.
Azelaic acid (AA) has been shown to interfere with DNA
synthesis in bacteria [18] and its oral toxicity in mice appears to be
low (.5 g/kg, data from DrugBank). In the present work, our
search suggests that AA may be able to interfere with two targets
involved in DNA repair within the P. falciparum apicoplast: a
peptide with a 59-39 exonuclease, N-terminal resolvase domain
(PF3D7_0203900) and a plastid replication-repair enzyme (PREX)
(PF3D7_1411400). Additionally, according to the data available in
the DrugBank database, AA has a log P value of 1.7, indicating
that the drug may diffuse well through biomembranes [8].
Although this property is not a pre-requisite for the success of
drugs targeting the apicoplast’s biology [8], it may come as a
benefit for apicoplast-targeting drugs, which have to cross a total of
six membranes. However, AA is used commercially in the form of
a topically applied cream and thus the practical aspects of testing it
as an antimalarial may present some challenges.
Lucanthone is one of the earliest described schistosomicides [19]
and was predicted to target the apicoplast’s putative AP-
endonuclease (PF3D7_0305600) in the present work. It was later
replaced largely by hycanthone, its active metabolite. Although
there are no records in the literature about the evaluation of
lucanthone’s antimalarial activity, hycanthone has been hypoth-
esized to possess antimalarial activity in a virtual screen against P.
falciparum with an IC50 value below 5 microM [20]. In the present
day lucanthone is used as an anti-cancer agent where it has been
shown to be well tolerated by humans with no hematological or
gastro-intestinal toxicity at clinically tolerated doses (data from
DrugBank). However, this contrasts with earlier suggestions where
in past shistosomiasis treatment with lucanthone was reported to
produce side effects such hepatotoxicity and gastrointestinal
disturbances following intramuscular injection [21].
Isoxyl (Thiocarlide), a thiourea derivative that was used
successfully for the clinical treatment of TB during the 1960s,
has been shown to display significant antimycobacterial activity
in vitro and is effective against multi-drug resistant strains of
Mycobacterium tuberculosis [22]. In Mycobacteria, isoxyl (ISO) has
been shown to inhibit the synthesis of oleic acid and this effect is
directly attributable to the inhibitory effect of the drug on the
membrane-associated stearoyl-coenzyme A (CoA) (D9) desaturase
DesA3 (Rv3229c) [23]. Results from the present work suggest that
isoxyl may also be able to inhibit the P. falciparum apicoplast
homologue (E-value = 2e252), a putative stearoyl-CoA delta 9
desaturase (PF3D7_0511200). Also, ISO has no known side-effects
[24], which makes it highly appropriate for clinical use in humans.
One likely downside of ISO is the fact that it has a high logP value
of <5.8 (http://www.chemspider.com/Chemical-Structure.
2272774.html), which makes it virtually insoluble in water with
consequent poor dissolution and bioavailability when it is
delivered exclusively by the oral route [24].
Figure 2. Distribution of the expected apicoplast targets
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Nitroxoline (synonym 5-Nitroxin) is an active urinary antibac-
terial agent which has been used since 1962 against susceptible
gram-positive and gram-negative organisms commonly found in
urinary tract infections [25]. It has been suggested that its
antibacterial activity may stem from the metal ion complexation
vital for bacterial growth [26]. More recently, it was discovered
that that nitroxoline has antiangiogenic properties, which also
makes it useful as an anti-cancer drug [27]. We found that
Nitroxoline may be able to interfere with the apicoplast-targeted P.
falciparum putative methionine aminopeptidase 1c
(PF3D7_0804400), which is homologous to the human enzyme
and is expected to be involved in proteolysis within the apicoplast.
Interestingly, nitroxiline was tested in early in vitro studies where it
was shown to display exceptional activity against P. falciparum,
exhibiting an ED50 of approximately 63 nM at 48h post-
exposure, a value which reflected roughly 10X higher potency
than quinine sulfate in that same study, under identical conditions
[28]. In addition to what appears to be a level of high potency
in vitro, nitroxoline displays a logP of 1.9 (data from DrugBank),
which should favor its ability to cross the membranes required to
reach its target. Curiously, the assessment of nitroxoline as a
potential antimalarial for clinical use in vivo appears to have never
been followed-up. For all reasons cited, we argue here that
nitroxoline should be prioritized for further evaluations of its
potential value as an antimalarial drug.
Lastly, we refer to sulcrafate, possibly one of the least obvious
drugs to hold antimalarial activity, due to the fact that it is not an
anti-infective agent per se, but rather an anti-ulcer compound.
Sulcrafate is an approved small molecule, which is a basic
aluminum complex of sulfated sucrose and is orally employed for
prevention and treatment of several gastrointestinal diseases
including gastroesophageal reflux, gastric and duodenal ulcer
[29]. Sucralfate acts, at least partially, through inhibition of the
human pepsin A enzyme [30], which was shown here to be
homologous to four P. falciparum plasmepsins localized to the
apicoplast (plasmepsin X: PF3D7_0808200, plasmepsin I (PMI):
PF3D7_1407900, plasmepsin III,histo-aspartic protease (HAP):
PF3D7_1408100 and plasmepsin VII: PF3D7_1033800). Inter-
estingly, halofantrine, a well-known highly effective antimalarial
has been recently suggested to inhibit plasmepsin X, one of
sulcrafate’s predicted targets [31]. Due to its own therapeutic
nature, sulcrafate is only minimally absorbed from the gastroin-
testinal tract (data from DrugBank) and consequently it is unlikely
to reach systemic therapeutic levels in patients treated orally.
However, since sulcrafate is commercially available in powder
form, it may be tested directly after dilution in an appropriate
vehicle in experimental in vivo models of malaria with administra-
tion via a route other than oral, such as intra-venous or intra-
peritoneal.
Besides the drugs highlighted above, eight further drugs are
predicted to be capable of interfering with apicoplast targets
(Table 2). They were not discussed in detail because we envisage
that some of their inherent properties may render them less
suitable than the above as antimalarial agents. For instance,
bleomycin, gemcitabine and gallium nitrate are three anti-
neoplastic agents and for this reason are more likely to cause
severe side-effects/toxicity in humans in case their direct use is
considered. Indeed, although gallium nitrate’s toxicity parameters
are not available, considerable toxicity is expected from bleomycin
and gemcitabine (Table 2). In other cases, such as those of
rifabutin and ethionamide, we considered that the output
expectation value (E-value) for target homology insufficiently
significant to infer the target’s prediction with a high degree of
confidence. Remikeren and aliskeren are two antihypertensive
agents and for that reason, should present increased challenges as
to their short-term applicability as antimalarials.
Conclusions
We describe a systematic in silico approach to identify drugs that
have been clinically approved for human use, but have never been
evaluated against malaria parasites based on the principle of
‘‘homologous drug target screening’’. In doing so, we were able to
identify thirteen such drugs that we suggest justify evaluation as
antimalarials. We stress the fact that we have no experimental
evidence to suggest that any of the newly identified drugs will
either display antimalarial activity and/or affect the suggested
targets. It also is possible that their in vivo potencies may be
compromised by absorption, distribution, metabolism, excretion
ad toxicity (ADMET) properties or by lack of appropriate
chemical affinity with their putative target(s). Nevertheless,
primary in vitro drug screens may provide insights into their ability
to inhibit parasite growth and, if any promising activities are
disclosed, they could constitute important leads to the discovery of
novel antimalarials.
Table 1. Examples of drug-target associations previously determined, that were correctly identified in the present study.
Drug(s) P. falciparum target(s) ID Identity to (E-value or score) Pathway Reference(s)
Several quinolones DNA GyrAse a-subunit, putative PF3D7_1223300 DNA gyrase subunit A (P72524 -
GYRA_STRPN) (1e250)
Replication [8]
Fusidic acid elongation factor G, putative
PF3D7_0602400
Elongation factor G (P13551 -
EFG_THETH) (8.7e275)
Translation [17]
Tetracycline apicoplast ribosomal protein S14p/S29e
precursor, putative PF3D7_1137500








Triclosan enoyl-acyl carrier reductase PF3D7_0615100 0.99 Fatty acid synthesis [8]
Geldanamycin heat shock protein 90, putative 0.80 Protein folding [33]
Halofantrine plasmepsin VIII PF3D7_1465700 Plasmepsin-2 (P46925 - PLM2_PLAFA)
(9e223)
Proteolysis [31]
(codes in brackets represent the target Identity Code of DrugBank. In the cases of Fosmidomycin, Triclosan and Geldanamycin, there are no homologous targets
represented because they were identified using STITCH3.1 which uses an algorithm where homologous targets are not displayed).
doi:10.1371/journal.pone.0059288.t001
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Supporting Information
Table S1 List of apicoplast-targeted proteins with
predicted aminoacid (AA) sequences.
(XLSX)
Table S2 Predicted targets list. (DB: DrugBank; TTD:
Therapeutic Targets Database: DS: dietary supplement or
nutraceutical. TDRT: Tropical Disease Research Targets; Blank
cells denote that no data was available).
(XLSX)
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A photosynthetic alveolate closely related to apicomplexan parasites. Nature
451(7181): 959–63.
7. Ralph SA, van Dooren GG, Waller RF, Crawford MJ, Fraunholz MJ, et al.
(2004) Tropical infectious diseases: metabolic maps and functions of the
Plasmodium falciparum apicoplast. Nat Rev Microbiol 2004 Mar;2(3): 203–16.
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